OSI Pharmaceuticals Inc. - About Lung Cancer

OSIP) today announced further results from the Phase III SATURN study showing that Tarceva? (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line ...